# IFm2022-01 (NCT06353022)

> Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06353022
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Nantes University Hospital
- Conditions: Multiple Myeloma
- Interventions: Teclistamab; Talquetamab; Lenalidomide; Bortezomib; Daratumumab; Dexamethasone
- Enrollment: 103
- Primary outcome: Rate of sustained MRD negativity (NGS, 10^-5)
- Primary outcome: Rate of conversion from positive MRD to negative MRD (NGS, 10^-5)

## Commentary we found

- X threads: 4
- YouTube: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ifm2022-01-nct06353022